Advertisement

Topics

Safety concerns sideline Seattle Genetics' cancer candidate

09:43 EDT 19 Jun 2017 | BioPharmaDive

The West Coast drugmaker stopped vadastuximab talirine investigations after the treatment arm of a Phase 3 study showed a higher rate of death.

Original Article: Safety concerns sideline Seattle Genetics' cancer candidate

NEXT ARTICLE

More From BioPortfolio on "Safety concerns sideline Seattle Genetics' cancer candidate"

Advertisement
Quick Search
Advertisement
Advertisement